What is In8Bio, Inc.'s earnings per share (EPS)?

In8Bio, Inc. (INAB) reported diluted earnings per share of $-4.44 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

In8Bio, Inc. Financials

INAB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows In8Bio, Inc. (INAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

In8Bio, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.65x

For every $1 of reported earnings, In8Bio, Inc. generates $0.65 in operating cash flow (-$12.7M OCF vs -$19.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$17.7M

YoY+38.2%

In8Bio, Inc.'s EBITDA was -$17.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.2% from the prior year.

Net Income

-$19.4M

YoY+36.1%

In8Bio, Inc. reported -$19.4M in net income in fiscal year 2025. This represents an increase of 36.1% from the prior year.

EPS (Diluted)

$-4.44

In8Bio, Inc. earned $-4.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 74.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$27.3M

YoY+139.9%

5Y CAGR+8.5%

In8Bio, Inc. held $27.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

10M

In8Bio, Inc. had 10M shares outstanding in fiscal year 2025. This represents an increase of 304.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-70.5%

YoY+139.7pp

In8Bio, Inc.'s ROE was -70.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 139.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.2M

YoY-39.8%

5Y CAGR+13.7%

In8Bio, Inc. invested $10.2M in research and development in fiscal year 2025. This represents a decrease of 39.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

INAB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.2M-39.8%	$17.0M+0.8%	$16.8M+19.7%	$14.1M+91.4%	$7.3M+36.6%	$5.4M
SG&A Expenses	$9.7M-23.6%	$12.6M-6.5%	$13.5M-6.6%	$14.5M+97.9%	$7.3M+129.8%	$3.2M
Operating Income	-$19.4M+36.1%	-$30.4M-1.4%	-$30.0M-5.2%	-$28.5M-94.6%	-$14.7M-71.2%	-$8.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$19.4M+36.1%	-$30.4M-1.4%	-$30.0M-5.2%	-$28.5M-94.6%	-$14.7M-71.2%	-$8.6M
EPS (Diluted)	$-4.44	$-17.05	$-1.00+26.5%	$-1.36+7.5%	$-1.47	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.1M-15.4%	$2.5M-16.3%	$3.0M	N/A	$3.3M-35.8%	$5.2M+5.2%	$4.9M
SG&A Expenses	N/A	$1.9M-31.4%	$2.7M+1.0%	$2.7M	N/A	$2.7M-22.7%	$3.5M-5.6%	$3.7M
Operating Income	N/A	-$3.9M+24.3%	-$5.1M+8.2%	-$5.5M	N/A	-$7.1M+17.9%	-$8.6M-0.8%	-$8.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.9M+24.3%	-$5.1M+8.2%	-$5.5M	N/A	-$7.1M+17.9%	-$8.6M-0.8%	-$8.6M
EPS (Diluted)	N/A	$-0.85+31.5%	$-1.24	$-0.07	N/A	$-4.49+18.5%	$-5.51-2655.0%	$-0.20

INAB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$32.3M+54.1%	$20.9M-37.9%	$33.7M+2.0%	$33.0M-21.8%	$42.2M+101.9%	$20.9M
Current Assets	$27.9M+121.7%	$12.6M-48.9%	$24.6M+10.8%	$22.2M-43.0%	$39.0M+114.8%	$18.1M
Cash & Equivalents	$27.3M+139.9%	$11.4M-47.1%	$21.5M+16.8%	$18.4M-50.5%	$37.3M+105.5%	$18.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.7M-26.9%	$6.5M-26.3%	$8.8M-14.9%	$10.3M-87.2%	$80.4M+114.5%	$37.5M
Current Liabilities	$3.2M+2.5%	$3.1M-42.8%	$5.4M-7.4%	$5.8M+158.1%	$2.3M-12.3%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$27.6M+90.3%	$14.5M-41.9%	$24.9M+9.7%	$22.7M+159.5%	-$38.2M-130.3%	-$16.6M
Retained Earnings	-$141.1M-16.0%	-$121.7M-33.4%	-$91.2M-49.0%	-$61.2M-87.2%	-$32.7M-81.2%	-$18.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$32.3M+92.5%	$16.8M-13.4%	$19.4M-2.5%	$19.9M-5.1%	$20.9M+31.2%	$16.0M-29.0%	$22.5M	N/A
Current Assets	$27.9M+136.9%	$11.8M-14.4%	$13.7M+8.0%	$12.7M+1.2%	$12.6M+87.6%	$6.7M-47.1%	$12.7M	N/A
Cash & Equivalents	$27.3M+149.2%	$11.0M-18.8%	$13.5M+11.0%	$12.2M+6.8%	$11.4M+167.3%	$4.3M-59.3%	$10.5M-21.1%	$13.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.7M+32.0%	$3.6M-13.4%	$4.1M-31.0%	$6.0M-7.3%	$6.5M-12.4%	$7.4M-16.9%	$8.9M	N/A
Current Liabilities	$3.2M+85.6%	$1.7M-12.8%	$2.0M-33.9%	$3.0M-4.1%	$3.1M-15.2%	$3.6M-23.6%	$4.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$27.6M+108.9%	$13.2M-13.5%	$15.2M+9.8%	$13.9M-4.2%	$14.5M+68.6%	$8.6M-37.0%	$13.6M-22.3%	$17.5M
Retained Earnings	-$141.1M-3.6%	-$136.2M-2.9%	-$132.3M-4.0%	-$127.2M-4.6%	-$121.7M-5.3%	-$115.5M-6.5%	-$108.4M	N/A

INAB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.7M+47.4%	-$24.1M-3.5%	-$23.3M+3.2%	-$24.1M-78.6%	-$13.5M-89.4%	-$7.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$187K+68.8%	-$600K+83.8%	-$3.7M-1099.0%	-$309K	$0
Financing Cash Flow	$28.6M+101.9%	$14.2M-47.6%	$27.0M+200.9%	$9.0M-72.7%	$33.0M+34.4%	$24.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$2.1M+39.3%	-$3.5M+10.3%	-$3.9M-25.8%	-$3.1M+22.5%	-$4.0M+34.1%	-$6.1M-0.3%	-$6.1M+23.1%	-$7.9M
Capital Expenditures	N/A	$0	$0	$0	N/A	$0-100.0%	$21K-58.0%	$50K
Free Cash Flow	N/A	-$3.5M+10.3%	-$3.9M-25.8%	-$3.1M	N/A	-$6.1M0.0%	-$6.1M+23.3%	-$8.0M
Investing Cash Flow	$0	$0	$0	$0+100.0%	-$33K	$0+100.0%	-$83K-16.9%	-$71K
Financing Cash Flow	$18.5M+1769.5%	$989K-81.2%	$5.3M+35.3%	$3.9M-65.2%	$11.2M+10754.3%	-$105K-103.1%	$3.4M+1319.9%	-$277K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INAB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-70.5%+139.7pp	-210.2%-89.9pp	-120.3%+5.1pp	-125.5%	N/A	N/A
Return on Assets	-60.2%+85.1pp	-145.3%-56.3pp	-89.0%-2.7pp	-86.3%-51.6pp	-34.7%+6.2pp	-40.9%
Current Ratio	8.82+4.7	4.08-0.5	4.57+0.7	3.82-13.5	17.28+10.2	7.05
Debt-to-Equity	0.17-0.3	0.45+0.1	0.35-0.1	0.45+2.6	-2.11+0.2	-2.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-29.2%+4.2pp	-33.4%+6.6pp	-40.0%	N/A	-82.5%-19.2pp	-63.3%-14.5pp	-48.9%
Return on Assets	N/A	-23.0%+3.3pp	-26.3%+1.6pp	-27.9%	N/A	-44.4%-6.0pp	-38.4%	N/A
Current Ratio	8.82+1.9	6.91-0.1	7.03+2.7	4.30+0.2	4.08+2.2	1.84-0.8	2.66	N/A
Debt-to-Equity	0.17-0.1	0.270.0	0.27-0.2	0.43-0.0	0.45-0.4	0.86+0.2	0.65	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Transcode Therapeutics Inc RNAZ

$7.9M

Processa Pharmaceuticals Inc PCSA

$7.4M

Cyclacel Phar Pr CYCCP

$9.6M

Aprea Therapeutics, Inc. APRE

$8.2M

Mustang Bio MBIO

$5.9M

Frequently Asked Questions

Is In8Bio, Inc. profitable?

No, In8Bio, Inc. (INAB) reported a net income of -$19.4M in fiscal year 2025.

What is In8Bio, Inc.'s EBITDA?

In8Bio, Inc. (INAB) had EBITDA of -$17.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is In8Bio, Inc.'s return on equity (ROE)?

In8Bio, Inc. (INAB) has a return on equity of -70.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is In8Bio, Inc.'s operating cash flow?

In8Bio, Inc. (INAB) generated -$12.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are In8Bio, Inc.'s total assets?

In8Bio, Inc. (INAB) had $32.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does In8Bio, Inc. spend on research and development?

In8Bio, Inc. (INAB) invested $10.2M in research and development during fiscal year 2025.

How many shares does In8Bio, Inc. have outstanding?

In8Bio, Inc. (INAB) had 10M shares outstanding as of fiscal year 2025.

What is In8Bio, Inc.'s current ratio?

In8Bio, Inc. (INAB) had a current ratio of 8.82 as of fiscal year 2025, which is generally considered healthy.

What is In8Bio, Inc.'s debt-to-equity ratio?

In8Bio, Inc. (INAB) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is In8Bio, Inc.'s return on assets (ROA)?

In8Bio, Inc. (INAB) had a return on assets of -60.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is In8Bio, Inc.'s cash runway?

Based on fiscal year 2025 data, In8Bio, Inc. (INAB) had $27.3M in cash against an annual operating cash burn of $12.7M. This gives an estimated cash runway of approximately 26 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is In8Bio, Inc.'s Piotroski F-Score?

In8Bio, Inc. (INAB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are In8Bio, Inc.'s earnings high quality?

In8Bio, Inc. (INAB) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.